Clinical Trial: Value of Various Chemokines in the Detection and Follow up of RCC

Study Status: Completed
Recruit Status: Unknown status
Study Type: Observational

Official Title: Value of Various Chemokines in the Detection and Follow up of RCC

Brief Summary: This study was designed as a pilot study to try and find a Chemokine that may be specific for renal cell carcinoma

Detailed Summary:

I n previous studies that were initiated in experimental models of different inflammatory autoimmune diseases and then extended to humans, we have shown that in the course of inflammatory autoimmune diseases, the immune system selectively generates an auto-Ab response to a few inflammatory mediators, mostly chemokines and cytokines, which are thought to participate in promoting the inflammatory process (1-6). For example, we showed that patients suffering from rheumatoid arthritis (RA) but not osteoarthritis display a significant level of neutralizing auto- Abs directed against TNF-a (tumor necrosis factor)(3). These patients did not mount any auto-Ab response either to several key inflammatory chemokines or to regulatory mediators, such as IL-10(interleukin-10) or TGF-b(tumor growth factor)(, or even the chemokine CXCL12(C-X-C motif chemokine 12), which also functions as a regulatory mediator that selects Ag-specific IL-10-producing CD4+(cluster of differentiation 4) T cells (7).

Complementary experiments suggested that in experimentally induced RA, these anti-TNF-a auto-Abs participate in the natural regulation of disease and restrain—although they are incapable of totally preventing—its development (3). Nevertheless, their selective amplification by targeted DNA vaccines led to rapid recovery from an ongoing disease (8). These studies also showed that selective breakdown of tolerance to TNF-a is due to its preferential expression at a partially immune-restricted site undergoing a destructive process (3, 8). Very recently, we have shown that type I diabetes mellitus (T1DM) patients preferentially display auto-Ab production to CCL3( Chemokine (C-C motif) ligand 3) and not to several other proinflammatory chemokines (9).

It is yet to be proven that this chemokine dominates the chemokine expression at the autoim
Sponsor: Carmel Medical Center

Current Primary Outcome: Measurement of the titers of chemokines before and after tumor resection [ Time Frame: before nephrectomy (day of surgery) ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Carmel Medical Center

Dates:
Date Received: October 30, 2013
Date Started: January 2014
Date Completion: November 2016
Last Updated: March 4, 2015
Last Verified: March 2015